Oncology Forecasting: A Different Kind of Challenge

Cancer doesn’t follow a straight path so your forecasts shouldn’t either. This new chapter in our Forecasting Methodologies eBook explores the complexity of oncology forecasting, from lines of therapy and biomarker segmentation to progression modeling and treatment exclusions. We address questions such as: What’s the best way to track patients through dynamic treatment pathways? How […]

Share:

Cancer doesn’t follow a straight path so your forecasts shouldn’t either. This new chapter in our Forecasting Methodologies eBook explores the complexity of oncology forecasting, from lines of therapy and biomarker segmentation to progression modeling and treatment exclusions.

We address questions such as:

  • What’s the best way to track patients through dynamic treatment pathways?
  • How can I account for restrictions and progression across lines?
  • How do I adapt my model to an evolving therapy landscape?

Includes a spotlight on PD-1 targeting therapies and their growing impact.

Download the eBook and rethink your oncology forecast.

Upcoming Webinar

China Pipelines, Western Portfolios

Tuesday 14th July 3pm BST | 10am ET

Western pharma committed close to $2 billion in licensing deals and acquisitions for China-originated assets in Q1 2026 alone.

Related Posts